WO2012175541A1 - Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide - Google Patents

Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide Download PDF

Info

Publication number
WO2012175541A1
WO2012175541A1 PCT/EP2012/061798 EP2012061798W WO2012175541A1 WO 2012175541 A1 WO2012175541 A1 WO 2012175541A1 EP 2012061798 W EP2012061798 W EP 2012061798W WO 2012175541 A1 WO2012175541 A1 WO 2012175541A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
deuterium
abr
compound according
pharmaceutically acceptable
Prior art date
Application number
PCT/EP2012/061798
Other languages
French (fr)
Inventor
Leif Svensson
Original Assignee
Active Biotech Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Active Biotech Ab filed Critical Active Biotech Ab
Priority to US14/125,666 priority Critical patent/US9216956B2/en
Priority to CN201280030397.8A priority patent/CN103796654B/en
Priority to KR1020147000764A priority patent/KR20140035493A/en
Priority to RU2014101775A priority patent/RU2608306C2/en
Priority to BR112013031712-4A priority patent/BR112013031712B1/en
Priority to AU2012274160A priority patent/AU2012274160B2/en
Priority to EP12728565.8A priority patent/EP2723340B1/en
Priority to CA2838947A priority patent/CA2838947A1/en
Priority to JP2014516322A priority patent/JP6034861B2/en
Publication of WO2012175541A1 publication Critical patent/WO2012175541A1/en
Priority to ZA2013/09733A priority patent/ZA201309733B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to deuterium enriched 4-hydroxy-5-methoxy-N, 1 -dimethyl-2- oxo-N-[(4-trifluoro-methyl)phenyl]- 1 ,2-dihydroquinoline-3-carboxamide, to pharmaceutically acceptable salts thereof, and to the use thereof in therapy.
  • ABR- 215050 The compound 4-hydroxy-5-methoxy-N,l-dimethyl-2-oxo-N-[(4-trifluoromethyl)phenyl]-l,2- dihydroquinoline-3-carboxamide (CAS# 254964-60-8, herein below also referred to as ABR- 215050) has shown efficacy in animal experiments relevant for cancer (1). It also has been shown that ABR-215050 is capable of inhibiting prostate tumor growth via a mechanism involving an anti-angiogenic response (2); a clear anti-tumor response has been achieved in a number of in vivo tumor models using human prostate cancer cell lines (3). This has encouraged further trials on the compound and efficacy in the treatment of human cancer has been shown in a phase 2 clinical trial (4).
  • ABR-215050 treatment also had an effect on bio markers relevant for prostate cancer progression and was generally well tolerated.
  • ABR-215050 also has an efficacy in the treatment of autoimmune diseases.
  • an in vivo animal experimental study has shown efficacy of the compound in the treatment of rheumatoid arthritis (5), and another one has shown its efficacy in the treatment of multiple sclerosis (6).
  • Deuterium ( 2 H or D) is a stable and non-radioactive isotope of hydrogen which has approximately twice the mass of protium (1H or H), the by far most common isotope of hydrogen. Deuteration of pharmaceuticals to improve pharmacokinetics (P ),
  • pharmacodynamics (PD), and toxicity profiles has been disclosed previously with some classes of drugs.
  • various deuteration patterns can be used to (a) reduce or eliminate unwanted metabolites, (b) increase the half-life of the parent drug, (c) decrease the number of doses needed to achieve a desired effect, (d) decrease the amount of a dose needed to achieve a desired effect, (e) increase the formation of active metabolites, if any are formed, (f) decrease the production of deleterious metabolites in specific tissues, and/or (g) create a more effective drug and/or a safer drug for polypharmacy, whether the polypharmacy be intentional or not.
  • deuteration of laquinimod is disclosed and it is stated that the deuteration approach has the strong potential to slow the metabolism of laquinimod.
  • the compound of the invention is according to formula (I)
  • R 1 is selected from H and pharmaceutically acceptable organic or inorganic cations
  • R 2 , R 3 and R 4 are independently selected from H and D;
  • CR 2 R 3 R 4 has a total deuterium enrichment of at least 70%.
  • R 1 , R 2 , R 3 and R 4 are as defined herein above;
  • the compound of the invention is useful as a medicament, e.g. for use in the treatment of a malignant hyperproliferative disease or an autoimmune disease.
  • the compound of the invention also is useful as a medicament, e.g. for use in the treatment of a disorder ameliorated by the modulation of immune function.
  • composition comprising a
  • inventive compound also is suitable for use in the prevention or treatment of a disorder selected from malignant hyperproliferative diseases and autoimmune diseases.
  • a method for the treatment of a mammal suffering from a malignant hyperproliferative disease also is provided. Furthermore, a method for the treatment of a mammal suffering from an autoimmune disease is provided, as well as a method for the treatment of a disorder that is ameliorated by the modulation of immune function.
  • Figure 1 is a graph representing the fold induction of luciferase expression as a function of added amounts of ABR-215050 and of its amide demethylation metabolite ABR-215691, respectively, in a human hepatoma cell line used in an in vitro luciferase gene reporter assay for the measurement of Ah mediated induction of CYP1A1.
  • Figure 2 is is a graph representing the fold induction of luciferase expression as a function of added amounts of benzo(a)pyrene in a human hepatoma cell line used in an in vitro luciferase gene reporter assay for the measurement of Ah mediated induction of CYP1A1.
  • Figure 3 is the structural formula of ABR-21 050, showing in bold the three methyl groups that are present in the compound and that herein are referred to as amide-N-methyl, quinoline- N-methyl and quinoline-O-methyl, respectively.
  • Figure 5 is a bar diagram showing the mean plasma level (in nM) of the amide-N
  • demethylated metabolite of ABR-215050 and of deuterium- enriched ABR-215050 wherein the amide-N methyl is deuterated herein below also referred to as ABR-215050-dx, respectively, after administration to rat of ABR-215050 and ABR-215050-dx in a (1 :1) mixture.
  • Figure 6 is a bar diagram showing the mean fold induction of CYPl Al and of CYPl A2 in rat after peroral administration of ABR-215050 and of ABR-215050-dx, with peroral
  • Figure 7 is a diagram showing the effect of orally administered ABR-215050-dx (10 mg/kg/day) on LNCaP tumor in Nude Balb/c mice.
  • ABR-215050 has shown promising results as a therapeutically active compound which may be useful in the treatment of various serious diseases.
  • ABR-215050 was tested with respect to its CYP 1 A inducing capability in vitro in a TV-cell assay.
  • This assay is a luciferase gene reporter assay developed for the measurement of AhR (Aryl hydrocarbon Receptor) mediated induction of CYPl A.
  • AhR Aryl hydrocarbon Receptor
  • Human CYPl A promoters and 5 '-flanking sequences were cloned into firefly luciferase expression vectors and stably integrated into the human hepatoma cell line, HepG2 (9). The isolated cell line was renamed TV101L. This test showed that ABR-215050 did not induce CYPl A, cf. herein below under "In vitro assay of CYPl A inducing capacity of ABR-215050".
  • ABR-219694 Three demethylation metabolites of ABR-215050 were found in the rat i.e. the quinoline-N demethylated metabolite, referred to herein below as ABR-219694, the quinoline-O demethylated metabolite ABR-222097, referred to herein below as ABR-222097, and the amide-N demethylated metabolite, referred to herein below as ABR-215691, cf. Table 1.
  • ABR-215691 had a substantial CYPIA inducing capacity, several magnitudes higher than that of the two other demethylated metabolites and the parent compound ABR-215050 itself, cf. herein below under "In vitro assay of CYP1A1 inducing capacity of ABR-215691". It could be suspected that even at a very low concentration, ABR-215691 could contribute substantially to CYPIA induction due to its very high inducing capacity.
  • ABR-215050 The water solubility of ABR-215050 and of its metabolites also was investigated. It is a well- known fact that metabolism in general aims to transform compounds to more water soluble entities (10), which mostly decreases toxicity but also facilitates renal elimination. Both ABR- 219694 and ABR-222097 were highly water soluble However, surprisingly ABR-215691 was found to have extremely low water solubility, compared to the other metabolites as well as to the parent compound, cf. Table 2.
  • ABR-215691 ⁇ 0.00001
  • the renal excretion of ABR-215691 is low, compared to that of the two other demethylation metabolites.
  • ABR-215050-dx the pharmacokinetic characteristics of the amide-N methyl deuterated ABR- 215050 (herein below referred to as ABR-215050-dx), wherein the amide-N methyl moiety was tri-deuterated, compared to the non-deuterated parent compound were studied in rat.
  • the in vivo formation of ABR-215691 was reduced to only 25% when ABR-215050-dx was used. It also was noted that the reduced amide-N
  • a deuterated ABR-215050 which on administration gives rise to a substantially reduced CYP1 A induction while providing a high therapeutic activity.
  • the term “deuterium enrichment” at a specific position of a compound refers to the percentage of incorporation of deuterium at that position in place of hydrogen.
  • a compound having a 90 % deuterium enrichment at a given position it is intended that 90 % of the molecules in a sample contain deuterium at the specified position.
  • the natural abundance of deuterium is about 0.0156%, which means that the natural deuterium enrichment at any specific position of a compound is 0.0156 %.
  • the deuterium enrichment can be determined using e.g.
  • the term “deuterium enrichment” refers to a mean value, based on the individual values for the positions in the moiety.
  • the deuteration enrichment at each individual position e.g. may be 85%, 92% and 93%, (or any other percentage values) the mean of which is 90%.
  • disorders ameliorated by the modulation of immune function e.g. comprise malignant hyperproliferative diseases, such as cancer, autoimmune diseases, inflammation and inflammatory diseases, and hypersensitivity disorders of the immune system.
  • метод ⁇ ии мо ⁇ ет ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇
  • squamous cell cancer e.g., epithelial squamous cell cancer
  • lung cancer including small-cell lung cancer, non-small cell lung cancer, adenocarcinoma of the lung and squamous carcinoma of the lung, cancer of the peritoneum, hepatocellular cancer, gastric or stomach cancer including gastrointestinal cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma, breast cancer, colon cancer, rectal cancer, colorectal cancer, endometrial cancer or uterine carcinoma, salivary gland carcinoma, kidney or renal cancer, prostate cancer, vulval cancer, thyroid cancer, hepatic carcinoma, anal carcinoma, penile carcinoma, as well as head and neck cancer.
  • squamous cell cancer e.g., epithelial squamous cell cancer
  • lung cancer including small-cell lung cancer, non-small cell lung cancer, adenocarcinoma of the lung and squamous carcinoma
  • autoimmune disease refers to any disorder that occurs when the tissues of a living body are attacked by the body's own immune system.
  • examples of autoimmune diseases are: Acute Disseminated
  • Encephalomyelitis Acute necrotizing hemorrhagic leukoencephalitis, Addison's disease, Agammaglobulinemia, Allergic asthma, Allergic rhinitis, Alopecia areata,
  • Amyloidosis Ankylosing spondylitis, Anti-GBM/Anti-TBM nephritis, Antiphospholipid syndrome (APS), Autoimmune aplastic anemia, Autoimmune dysautonomia, Autoimmune hepatitis, Autoimmune hyperlipidemia, Autoimmune immunodeficiency, Autoimmune inner ear disease (AIED), Autoimmune myocarditis, Autoimmune pancreatitis, Autoimmune retinopathy, Autoimmune thrombocytopenic purpura (ATP), Autoimmune thyroid disease, Axonal & neuronal neuropathies, Balo disease, Behcet's disease, Bullous pemphigoid, Cardiomyopathy, Castleman disease, Celiac sprue, Chagas disease, Chronic fatigue syndrome, Chronic inflammatory demyelinating polyneuropathy (CIDP), Chronic recurrent multifocal ostomyelitis (CRMO), Churg-Strauss syndrome, Cicatricial pe
  • encephalitis Hashimoto's thyroiditis, Hemolytic anemia, Henoch- Schonlein purpura, Herpes gestationis, Hypogammaglobulinemia, Idiopathic thrombocytopenic purpura (ITP), IgA nephropathy, IgG4-related sclerosing disease, Immunoregulatory lipoproteins, Inclusion body myositis, Insulin-dependent diabetes (typel), Interstitial cystitis, Juvenile arthritis, Juvenile diabetes, Kawasaki syndrome, Lambert-Eaton syndrome, Leukocytoclastic vasculitis, Lichen planus, Lichen sclerosus, Ligneous conjunctivitis, Linear IgA disease (LAD), Systemic Lupus Erythematosus (SLE), chronic Lyme disease, Meniere's disease, Microscopic polyangiitis, Mixed connective tissue disease (MCTD), Mooren's ulcer, Mucha-Habermann disease, Multiple sclerosis, Myas
  • Streptococcus Paraneoplastic cerebellar degeneration, Paroxysmal nocturnal hemoglobinuria (PNH), Parry Romberg syndrome, Parsonnage-Turner syndrome, Pars planitis (peripheral uveitis), Pemphigus, Peripheral neuropathy, Perivenous encephalomyelitis, Pernicious anemia, POEMS syndrome, Polyarteritis nodosa, Type I, II, & III autoimmune polyglandular syndromes, Polymyalgia rheumatica, Polymyositis, Postmyocardial infarction syndrome, Postpericardiotomy syndrome, Progesterone dermatitis, Primary biliary cirrhosis, Primary sclerosing cholangitis, Psoriasis, Psoriatic arthritis, Idiopathic pulmonary fibrosis, Pyoderma gangrenosum, Pure red cell aplasia, Raynauds phenomenon, Reflex sympathetic dystrophy, Re
  • Takayasu's arteritis Temporal arteritis/Giant cell arteritis, Thrombocytopenic purpura (TTP), Tolosa-Hunt syndrome, Transverse myelitis, Ulcerative colitis, Undifferentiated connective tissue disease (UCTD), Uveitis, Vasculitis, Vesiculobullous dermatosis, Vitiligo, and Wegener's granulomatosis (11).
  • hypersensitivity disorder refers to a disorder such as allergy.
  • allergy examples include atopic dermatitis, allergic urticarial, hay fever, allergic asthma, anaphylaxis, food allergy (milk, egg, peanut, tree nut, seafood, soy, wheat), penicillin allergy, etc
  • mammal includes a human as well as a non-human mammal, e.g. a horse, a pet animal, such as a cat or dog, a farm animal, such as a cow or sheep, or a laboratory animal such as a rat or monkey.
  • a non-human mammal e.g. a horse, a pet animal, such as a cat or dog, a farm animal, such as a cow or sheep, or a laboratory animal such as a rat or monkey.
  • the mammal is a human.
  • treatment includes prophylaxis as well as relieving the symptoms of disease.
  • the term encompasses not only treating a patient to relieve the patient of the signs and symptoms of the disease or condition, or to ameliorate the condition of the patient suffering from the disease or disorder, but also prophylactically treating an asymptomatic patient to prevent the onset or progression of the disease or condition.
  • the term "effective amount” refers to an amount of a compound, which confers a therapeutic effect on the treated patient.
  • the effect may be objective (i.e. measurable by some test or marker) or subjective (i.e. the subject gives an indication of or feels an effect).
  • the deuterium enrichment in the amide-N methyl group is at least 75%, or at least 80%, or at least 85%, e.g. at least 90%, or at least 95%, or at least 97%.
  • the inventive compound is deuterated also at one or more other positions, i.e. it comprises a D instead of a H at a specific position which is not in the amide- N methyl moiety, at a deuterium enrichment in excess of 0.0156 %.
  • a method of preparing a compound as defined herein above by reacting a 4-hydroxy-5-methoxy-l-methyl-2-oxo-l,2-dihydro-quinoline-3-carboxylic acid C 1 -C4 alkyl ester with deuterated N-methyl-p-trifluoromethylaniline having a deuterium enrichment in the amide N-methyl group of at least 70%; in a suitable solvent; and optionally reacting the compound with a suitable pharmaceutically acceptable base.
  • the deuterium enrichment in the N methyl group of N-methyl-p- trifluoromethylaniline is at least 75%, or at least 80%, or at least 85%, e.g. at least 90%, or at least 95%, or at least 97%.
  • either 4-hydroxy-5-methoxy-l-methyl-2-oxo-l,2-dihydro-quinoline-3- carboxylic acid C 1 -C4 alkyl ester or N-methyl-p-trifluoromethylaniline, or both, is deuterated at one or more further positions.
  • the "amide N" of 4-hydroxy-5-methoxy-N,l-dimethyl-2-oxo-N-[(4-trifluoromethyl)phenyl]- l,2-dihydro-quinoline-3-carboxamide also could be referred to as the "carboxamide N", i.e. it is the nitrogen of the 3-carboxamide moiety linking the phenyl ring moiety of the compound to the quinoline ring moiety.
  • the "amide N-methyl” could also be referred to as the
  • Carboxamide N-methyl is the methyl group attached to the (carbox)amide nitrogen.
  • the pharmaceutically acceptable salt of the compound of the invention may be e.g. a base addition salt derived from sodium hydroxide, potassium hydroxide, calcium hydroxide, monoethanolamine, diethanolamine, dimethylaminoethanol or morpholine. und has the formula (I)
  • R is selected from H and pharmaceutically acceptable organic or inorganic cations; and R 2 , R 3 and R 4 are independently selected from H and D; and
  • CR 2 R 3 R 4 has a total deuterium enrichment of at least 70%.
  • R 1 is H. In other embodiments, R 1 is selected from pharmaceutically acceptable organic or inorganic cations, e.g. cations derived from sodium, potassium, calcium, monoethanolamine, diethanolamine, dimethylaminoethanol, and morpholine.
  • pharmaceutically acceptable organic or inorganic cations e.g. cations derived from sodium, potassium, calcium, monoethanolamine, diethanolamine, dimethylaminoethanol, and morpholine.
  • R 2 , R 3 and R 4 are independently selected from H and D, each one of R 2 , R 3 and R 4 having a deuterium enrichment such that CR 2 R 3 R 4 has a total deuterium enrichment of about at least 70%.
  • the deuterium enrichment of CR 2 R 3 R 4 is at least about 75%, or at least about 80%, or at least about 85%, e.g. at least about 90%, or at least about 95%, or at least about 97%.
  • each one of R 2 , R 3 and R 4 should be at least about 89%; and for a deuterium enrichment of at least 97%, the deuterium enrichment of each one of R 2 , R 3 and R 4 should be at least about 99%.
  • R 2 is selected from H and D and CR 2 3 has a deuterium enrichment of at least 70%, or at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 97%.
  • any of the other hydrogen atoms of the compound according to formula (I) also may be exchanged for a deuterium. That is, in addition to R 2 , R 3 and R 4 , the compound of formula (I) may comprise up to 13 (when R 1 is not H) or 14 (when Rl is H) further deuterium atoms replacing hydrogens in the compound of formula (I). Indeed, due to the natural distribution of deuterium a small fraction of the molecules in any given sample of the compound of formula (I) will comprise one or several deuterium atoms. However, the presence of such further deuterium atoms, either naturally or not, is not critical to the invention.
  • the compound of formula (I) comprises at least one further deuterium atom at any specific location, other than in the amide-N methyl group, at a deuterium enrichment in excess of that which is naturally occurring, i.e. at an enrichment in excess of 0.0156 %, for example a deuterium enrichment of at least 1 %, or at least 5%, e.g. at least 10%.
  • This further deuterium atom may replace a hydrogen atom at any location of the compound of formula (I).
  • one or more hydrogen atoms attached to any of the quinoline-N methyl group or the quinoline-O methyl group of the compound of formula (I) may be replaced by deuterium, and/or any of the aromatic hydrogens of the compound of formula (I) may be replaced by a deuterium.
  • R 5 is a C1-C4 alkyl group
  • R 2 , R 3 and R 4 are as defined herein above,
  • R 5 may be a CI-C4 alkyl group, e.g. a CI -C3 alkyl group, such as methyl or ethyl, in particular methyl.
  • the compound of formula (II) may comprise a deuterium at one or more locations at a deuterium enrichment in excess of that which is naturally occurring.
  • any of the aromatic hydrogens may be replaced by a deuterium atom at a deuterium enrichment in excess of that which is naturally occurring.
  • the reaction between the compounds of formula (II) and (III) is performed in a suitable solvent medium.
  • the reaction solvent medium may be e.g. a hydrocarbon such as a straight or branched chain C7-C10 alkane or a cycloalkane or a mixture of thereof, e.g. heptane, octane or decahydronaphthalene.
  • the invention provides a compound for use in the treatment of a malignant hyperproliferative condition, e.g. selected from melanoma, carcinoma, lymphoma, blastoma, sarcoma, and leukemia or lymphoid malignancies.
  • a malignant hyperproliferative condition selected from melanoma, carcinoma, lymphoma, blastoma, sarcoma, and leukemia or lymphoid malignancies.
  • the invention provides a compound for use in the treatment of a malignant hyperproliferative condition selected from squamous cell cancer (e.g., .
  • lung cancer including small-cell lung cancer, non-small cell lung cancer, adenocarcinoma of the lung and squamous carcinoma of the lung, cancer of the peritoneum, hepatocellular cancer, gastric or stomach cancer including gastrointestinal cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma, breast cancer, colon cancer, rectal cancer, colorectal cancer, endometrial cancer or uterine carcinoma, salivary gland carcinoma, kidney or renal cancer, prostate cancer, vulval cancer, thyroid cancer, hepatic carcinoma, anal carcinoma, penile carcinoma, and head and neck cancer.
  • lung cancer including small-cell lung cancer, non-small cell lung cancer, adenocarcinoma of the lung and squamous carcinoma of the lung, cancer of the peritoneum, hepatocellular cancer, gastric or stomach cancer including gastrointestinal cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder
  • the malignant hyperproliferative disease is selected from a solid tumor, malignant melanoma or a hematological tumor.
  • the solid tumour is selected from adenocarcinoma, e.g. prostatic, breast, lung and colon-rectum cancers.
  • adenocarcinoma e.g. prostatic, breast, lung and colon-rectum cancers.
  • the invention provides a compound for use in the treatment of an autoimmune disease, e.g an autoimmune disease as defined herein above.
  • the autoimmune disease is selected from Crohn's disease, multiple sclerosis, rheumatoid arthritis, ulcerative colitis and systemic lupus erythematosus.
  • XREs xenobiotic responsive elements
  • a luciferase gene reporter assay was used for the measurement of AhR mediated induction of CYP1A1.
  • Human CYP1A1 promoters and 5 ' -flanking sequences were cloned into firefly luciferase expression vectors and stably integrated into the human hepatoma cell line, HepG2 (8).
  • the isolated cell line was renamed TV 1 OIL.
  • the cells were seeded in 96 well tissue culture plates 24-48 hours prior to treatment with the test compound. After the addition of ABR-215050 at a concentration of 1, 10 and 100 ⁇ , the cells were further incubated for 12-24 hours. The cells were harvested by the addition of lysis buffer followed by a freezing/thawing cycle. An enzymatic assay was used for the determination of lucif erase activity. The results, expressed as the fold induction of lucif erase expression, are shown in Table 3 and in Fig. 1.
  • a deuterated (also referred to as deuterium-enriched) ABR-215050 was synthesized, wherein the amide-N methyl moiety was trideuterated (ABR-215050-dx).
  • This deuterated compound was diluted with non-deuterated ABR-215050 to a molar ratio of 1 : 1.
  • the 1 : 1 equivalent molar mixture was administrated to rats in an in vivo experiment. Because of additional 13- carbon labeling in the quinoline scaffold, the formed amide-N demethyl metabolites could be measured selectively by means of HPLC-MS (High performance Liquid Chromatography with Mass Spectrometric detection).
  • HPLC-MS High performance Liquid Chromatography with Mass Spectrometric detection
  • the plasma levels of the ABR-215691 derived from ABR-215050-dx and ABR-215050 also were determined using LC-MS/MS and the results are shown in Table 6, which also shows the calculated ratio of the plasma levels of ABR-215691 derived from ABR-215050-dx and from ABR-215050, respectively as well as the calculated reduction of formation of amide-N demethyl metabolite.
  • Test preparations B and C and blank preparation A were made as follows: For preparation B, ABR-215050 was dissolved in NaOH and sterile water at a concentration of 0.5 mg/mL. The pH of the solution was adjusted to pH 7.4-8.5. Preparation C was made in the same way, using ABR-215050-dx. Preparation A was a blank containing only water. The preparations were stored in a refrigerator for a maximum of one week before use. Table 7 summarizes preparation data.
  • test animals On arrival at the laboratory, the test animals were 9 weeks old Sprague Dawley male rats having a body weight of 250 g. They were divided into 3 groups and were allowed to acclimatize for at least 7 days before the test. During the whole acclimatization and test period, the animals received water and feed (Labfor R70, form Kimstad, Sweden) ad libitum, and were kept under a 12 hours dark/12 hours light cycle, at a temperature of 20 ⁇ 2°C and a relative humidity of 50 ⁇ 15 %.
  • the animals were observed twice a day and weighed once a day. At any sign of reduced general condition, or at a weight loss of more than 15%, the rat was euthanized.
  • a blood sample was taken from vena saphena of rat No. 5.
  • blood samples were taken in heparinized tubes in order to analyze the plasma levels of the administered compounds and amide-N demethylated metabolite.
  • the samples were withdrawn from vena saphena (approx. 250 iL of blood) and from vena cava (maximum volume possible) according to the schedule indicated in Table 9.
  • the sample is taken 4 hours before administration of final dose.
  • the samples were cooled in ice water and centrifuged at 1300xg, +4°C for 10 minutes as soon as possible after withdrawal (within 30 minutes). Plasma was collected, frozen and kept at -70°C until analysis.
  • the animals were weighed and from each animal a final blood sample was withdrawn for a pharmacokinetic analysis. The animals then were euthanized and from each one the liver was withdrawn, weighed, and immediately frozen in crushed dry ice. The livers then were stored at -70°C until preparation of microsomes.
  • Microsomes were prepared according to the method M-0287 "Preparation of subcellular fractions from animal tissues” and then kept at -70°C until analysis.
  • the total protein concentration of the microsomal fraction was determined according to the method M-0289 "Determination of Protein according to Hartree".
  • the CYP1A1/2 enzyme activity was determined by incubation of the microsomal fraction with methoxyresorufin (MROD) and ethoxyresorufin (EROD), as CYP substrates, according to the method M-0272A, whereby EROD shows a higher specificity for CYP1A1, while MROD shows a higher specificity for CYP1A2.
  • MROD methoxyresorufin
  • EROD ethoxyresorufin
  • the anti-tumor effect of deuterated ABR-215050 was studied in mouse. Cell lines and culture conditions
  • the castration resistant subline LNCaP-19 was previously established from LNCaP cells (12). Cells were maintained as previously described (13). The LNCaP-19 cells were between passage 10 and 23 when used in the experiments. Passage 1 is defined as the first passage in our laboratory. The cells were tested and found free from mycoplasma.
  • mice Male athymic Nude BALB/c mice (age 8 weeks) were purchased from Taconic (Lille).
  • the present invention is further illustrated in the following non-limiting Example.
  • N-deuteriomethyl-p-trifluoromethylaniline was prepared as follows. 4- aminobenzotrifluoride (12.6 mL, 100 mmol) was dissolved in THF (100 mL) and
  • trifluoroacetic anhydride (21.2 mL, 150 mmol) was added portionwise while cooling on an ice-bath. After complete addition the mixture was evaporated to give the trifluoroacetamide derivative as a white solid (26.1 g). This solid was dissolved in THF (100 mL) and cooled on an ice-bath. Potassium tert-butoxide (180 mmol, 20.2 g) and then deuterio methyl iodide (25 g, 173 mmol) were added portionwise followed by stirring at room temperature for 18 hours. The mixture was evaporated and partitionated between diethyl eter and water. The organic extract was washed with water and then brine and dried over sodium sulphate.
  • the deuterated ABR-215050 according to the invention has a substantially reduced CYP1A inducing effect
  • the present invention in particular enables combination therapy with drugs that are susceptible of metabolization by CYP1A.
  • the two components may be in the same formulation or in separate formulations for administration simultaneously or sequentially.
  • the compounds of the present invention may also be used or administered in combination with other treatment such as irradiation for the treatment of cancer.
  • Cytochrome P450 CYP1A induction will allow for a possibility of increasing the dosage of ABR-215050 (in the amide-N methyl deuterated form), if this should be desired, even in the presence of drugs that are metabolised by CYP1A.
  • a method for the treatment of a mammal suffering from of a disorder ameliorated by the modulation of immune function which comprises administering to the mammal an effective amount of a compound according to the invention, or a pharmaceutically acceptable salt thereof.
  • the treatment includes prophylaxis as well as relieving the symptoms of disease or disorder.
  • the treatment is for relieving the symptoms of the disease, i.e.
  • a malignant hyperproliferative disorder e.g a malignant hyperproliferative disorder as mentioned herein above, or an autoimmune disease, e.g an autoimmune disease as mentioned herein above, in a mammal by administering to the mammal an effective amount of a compound according to the invention, or a pharmaceutically acceptable salt thereof.
  • Effective quantities of the compounds of formula (I) are preferably administered to a patient in need of such treatment according to usual routes of administration and formulated in usual pharmaceutical compositions comprising an effective amount of the active ingredient and a suitable pharmaceutically acceptable carrier.
  • Such compositions may take a variety of forms, e.g. solutions, suspensions, emulsions, tablets, capsules, and powders prepared for oral administration, aerosols for inhalations, sterile solutions for parental administration, and suppositories for rectal administration or suitable topical formulations.
  • Conventional procedures for the selection and preparation of suitable pharmaceutical formulations are described, for example, in "Aulton's Pharmaceutics: The Design and Manufacture of Medicines", M.E. Aulton, Churchill Livingstone, 2007.
  • a suitable daily dose for use in the treatment of cancer or an autoimmune disease is contemplated to vary between 0.0001 mg/kg to about 0.5 mg/kg body weight, in particular between 0.001 mg/kg to 0.05 mg/kg body weight, depending upon the specific condition to be treated, the age and weight of the specific patient, and the specific patient's response to the medication.
  • the exact individual dosage, as well as the daily dosage, will be determined according to standard medical principles under the direction of a physician.
  • the pharmaceutical composition may also contain additional therapeutically useful substances other than a compound of formula (I).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)

Abstract

Deuterium-enriched 4-hydroxy-5-methoxy-N,1-dimethyl-2-oxo-N-[(4-trifluoromethyl)- phenyl]-1,2-dihydroquinoline-3-carboxamide, having a deuterium enrichment in the amide-N methyl group of at least 70%; or a salt thereof with a pharmaceutically acceptable organic or inorganic cation; and a method of preparing said compounds. The compounds are useful in therapy, e.g. for the treatment of a malignant hyperproliferative disorder or an autoimmune disease.

Description

DEUTERIUM-ENRICHED 4-HYDROXY-5-METHOXY-N,l-DIMETHYL-2-OXO-N-[(4- TRIFLUORO-METHYL)PHENYL] - 1 ,2-DIHYDROQUINOLINE-3-CARBOXAMIDE
Field of the invention
The present invention relates to deuterium enriched 4-hydroxy-5-methoxy-N, 1 -dimethyl-2- oxo-N-[(4-trifluoro-methyl)phenyl]- 1 ,2-dihydroquinoline-3-carboxamide, to pharmaceutically acceptable salts thereof, and to the use thereof in therapy.
Background of the invention
The compound 4-hydroxy-5-methoxy-N,l-dimethyl-2-oxo-N-[(4-trifluoromethyl)phenyl]-l,2- dihydroquinoline-3-carboxamide (CAS# 254964-60-8, herein below also referred to as ABR- 215050) has shown efficacy in animal experiments relevant for cancer (1). It also has been shown that ABR-215050 is capable of inhibiting prostate tumor growth via a mechanism involving an anti-angiogenic response (2); a clear anti-tumor response has been achieved in a number of in vivo tumor models using human prostate cancer cell lines (3). This has encouraged further trials on the compound and efficacy in the treatment of human cancer has been shown in a phase 2 clinical trial (4).
In a recent, randomized placebo-controlled double blind phase II clinical study of ABR- 215050 in patients with asymptomatic metastatic castrate-resistant prostate cancer, a difference was shown in the number of patients with disease progression at six months.
Indeed, the results showed that the fraction of patients with disease progression during the six month period was 31% for patients treated with ABR-215050, compared to 66% for placebo treated patients (p<0.0001). The median progression free survival was 7.6 months for the group treated with ABR-215050, compared to 3.2 months for the placebo group (p=0.0009).
ABR-215050 treatment also had an effect on bio markers relevant for prostate cancer progression and was generally well tolerated.
In vivo animal experiments further have shown that ABR-215050 also has an efficacy in the treatment of autoimmune diseases. Thus, an in vivo animal experimental study has shown efficacy of the compound in the treatment of rheumatoid arthritis (5), and another one has shown its efficacy in the treatment of multiple sclerosis (6). Deuterium (2H or D) is a stable and non-radioactive isotope of hydrogen which has approximately twice the mass of protium (1H or H), the by far most common isotope of hydrogen. Deuteration of pharmaceuticals to improve pharmacokinetics (P ),
pharmacodynamics (PD), and toxicity profiles has been disclosed previously with some classes of drugs. For example, it has been disclosed (7) that various deuteration patterns can be used to (a) reduce or eliminate unwanted metabolites, (b) increase the half-life of the parent drug, (c) decrease the number of doses needed to achieve a desired effect, (d) decrease the amount of a dose needed to achieve a desired effect, (e) increase the formation of active metabolites, if any are formed, (f) decrease the production of deleterious metabolites in specific tissues, and/or (g) create a more effective drug and/or a safer drug for polypharmacy, whether the polypharmacy be intentional or not. In (7), therefore, deuteration of laquinimod is disclosed and it is stated that the deuteration approach has the strong potential to slow the metabolism of laquinimod.
Summary of the invention
According to a first aspect, there is provided a compound which is deuterium-enriched 4- hydroxy-5-methoxy-N, 1 -dimethyl-2-oxo-N-[(4-trifluoromethyi)phenyl]- 1 ,2-dihydro- quinoline-3-carboxamide, having a deuterium enrichment in the amide-N methyl group of at least 70%; or a pharmaceutically acceptable salt thereof.
There also is provided a method for preparing a deuterium-enriched 4-hydroxy-5-methoxy- N,l-dimethyl-2-oxo-N-[(4-trifluoromethyl)phenyl]-l,2-dihydro-quinoline-3-carboxamide having a deuterium enrichment in the amide-N methyl group of at least 70%; or a
pharmaceutically acceptable salt thereof, by reacting a 4-hydroxy-5-methoxy-l -methyl-2-oxo- l,2-dihydro-quinoline-3-carboxylic acid C1-C4 alkyl ester with deuterated N-methyl-p- trifluoromethylaniline having a deuterium enrichment in the N-methyl group of at least 70%; in a suitable solvent; and optionally reacting the obtained compound with a suitable pharmaceutically acceptable base.
In one embodiment, the compound of the invention is according to formula (I)
Figure imgf000003_0001
wherein
R1 is selected from H and pharmaceutically acceptable organic or inorganic cations;
R2, R3 and R4 are independently selected from H and D; and
CR2R3R4 has a total deuterium enrichment of at least 70%.
There also is provided a method for preparing a compound according to formula (I)
Figure imgf000004_0001
wherein R1, R2, R3 and R4 are as defined herein above;
comprising reacting a compound of formula (II)
Figure imgf000004_0002
wherein Rs is a C1-C4 alkyl group;
(III)
Figure imgf000004_0003
in a suitable solvent; so as to obtain a compound of formula (I) wherein Rl is H;
and optionally reacting the compound of formula (I) wherein R1 is H, with a suitable, pharmaceutically acceptable base.
The compound of the invention is useful as a medicament, e.g. for use in the treatment of a malignant hyperproliferative disease or an autoimmune disease.
The compound of the invention also is useful as a medicament, e.g. for use in the treatment of a disorder ameliorated by the modulation of immune function.
Consequently, there also is provided a pharmaceutical composition comprising a
therapeutically effective amount of a compound according to the invention. The inventive compound also is suitable for use in the prevention or treatment of a disorder selected from malignant hyperproliferative diseases and autoimmune diseases.
A method for the treatment of a mammal suffering from a malignant hyperproliferative disease also is provided. Furthermore, a method for the treatment of a mammal suffering from an autoimmune disease is provided, as well as a method for the treatment of a disorder that is ameliorated by the modulation of immune function.
Brief description of the drawings
Figure 1 is a graph representing the fold induction of luciferase expression as a function of added amounts of ABR-215050 and of its amide demethylation metabolite ABR-215691, respectively, in a human hepatoma cell line used in an in vitro luciferase gene reporter assay for the measurement of Ah mediated induction of CYP1A1. Figure 2 is is a graph representing the fold induction of luciferase expression as a function of added amounts of benzo(a)pyrene in a human hepatoma cell line used in an in vitro luciferase gene reporter assay for the measurement of Ah mediated induction of CYP1A1.
Figure 3 is the structural formula of ABR-21 050, showing in bold the three methyl groups that are present in the compound and that herein are referred to as amide-N-methyl, quinoline- N-methyl and quinoline-O-methyl, respectively.
Figure 4 is an electro spray ionization, positive mode, (ESI+) mass spectrum of ABR-215050 having a deuterated amide-N methyl group. Deuterium enrichment about 97%. Fraction of deuterium enriched compound represented in mass peak (protonated molecule, [M+H] +) at m/z=410 and fraction of not deuterium enriched compound represented in mass peak at m/z=407 (3% relative to m/z=410). The mass peak at m/z=432 is a molecular ion adduct formed due to sodium inonization [M+Na] +. The mass peaks at m/z = 411, 412, 413 and 433 reflect the natural abundance of the isotopes 13C, 15N, 170 and 180.
Figure 5 is a bar diagram showing the mean plasma level (in nM) of the amide-N
demethylated metabolite of ABR-215050 and of deuterium- enriched ABR-215050 wherein the amide-N methyl is deuterated, herein below also referred to as ABR-215050-dx, respectively, after administration to rat of ABR-215050 and ABR-215050-dx in a (1 :1) mixture.
Figure 6 is a bar diagram showing the mean fold induction of CYPl Al and of CYPl A2 in rat after peroral administration of ABR-215050 and of ABR-215050-dx, with peroral
administration of normal drinking water as blank.
Figure 7 is a diagram showing the effect of orally administered ABR-215050-dx (10 mg/kg/day) on LNCaP tumor in Nude Balb/c mice.
Detailed description of the invention
As noted herein above, ABR-215050 has shown promising results as a therapeutically active compound which may be useful in the treatment of various serious diseases. ABR-215050 was tested with respect to its CYP 1 A inducing capability in vitro in a TV-cell assay. This assay is a luciferase gene reporter assay developed for the measurement of AhR (Aryl hydrocarbon Receptor) mediated induction of CYPl A. Human CYPl A promoters and 5 '-flanking sequences were cloned into firefly luciferase expression vectors and stably integrated into the human hepatoma cell line, HepG2 (9). The isolated cell line was renamed TV101L. This test showed that ABR-215050 did not induce CYPl A, cf. herein below under "In vitro assay of CYPl A inducing capacity of ABR-215050".
Three demethylation metabolites of ABR-215050 were found in the rat i.e. the quinoline-N demethylated metabolite, referred to herein below as ABR-219694, the quinoline-O demethylated metabolite ABR-222097, referred to herein below as ABR-222097, and the amide-N demethylated metabolite, referred to herein below as ABR-215691, cf. Table 1.
Figure imgf000006_0001
Figure imgf000007_0001
These metabolites too were tested in the TV-cell assay. Just like ABR-215050, ABR-219694 and ABR-222097 were found not to induce CYP IA (data not shown). Surprisingly, it was found that in contrast to the parent compound and the two other demethylation metabolites, ABR-215691 had a substantial CYPIA inducing capacity, several magnitudes higher than that of the two other demethylated metabolites and the parent compound ABR-215050 itself, cf. herein below under "In vitro assay of CYP1A1 inducing capacity of ABR-215691". It could be suspected that even at a very low concentration, ABR-215691 could contribute substantially to CYPIA induction due to its very high inducing capacity.
The water solubility of ABR-215050 and of its metabolites also was investigated. It is a well- known fact that metabolism in general aims to transform compounds to more water soluble entities (10), which mostly decreases toxicity but also facilitates renal elimination. Both ABR- 219694 and ABR-222097 were highly water soluble However, surprisingly ABR-215691 was found to have extremely low water solubility, compared to the other metabolites as well as to the parent compound, cf. Table 2.
Table 2 Water solubility of ABR-215050 and ABR-215691
Compound Water solubility at pH 7 (mg/mL)
ABR-215050 0.5
ABR-215691 < 0.00001 In view of this low water solubility of ABR-215691 it may be expected that the renal excretion of ABR-215691 is low, compared to that of the two other demethylation metabolites. Together, the above findings indicate that CYP1A induction through ABR- 215691 could eventually cause a drug to drug interaction problem in man in vivo that, even if not insurmountable, must nonetheless be seriously considered in medical treatment.
Therefore, the pharmacokinetic characteristics of the amide-N methyl deuterated ABR- 215050 (herein below referred to as ABR-215050-dx), wherein the amide-N methyl moiety was tri-deuterated, compared to the non-deuterated parent compound were studied in rat. The reduction of the metabolic amide-N demethylation when the amide-N methyl was deuterium labeled was very pronounced; the formation of demethylated metabolite was diminished by as much as a factor of four compared to the non-deuterium labeled ABR-215050. In other words: relative to ABR-215050, the in vivo formation of ABR-215691 was reduced to only 25% when ABR-215050-dx was used. It also was noted that the reduced amide-N
demethylation did not affect the 1 : 1 molar ratio for the parent drugs in vivo in plasma, meaning that the positive disease remedy effects are sustained but the undesired side effect consisting of CYP1A induction is depressed, cf. herein below under "In vivo investigation of pharmacokinetic characteristics of ABR-215050 and ABR-215050-dx in rat". Further in vivo studies in rat show that CYP1A induction is substantially reduced by administration of ABR-215050-dx instead of ABR-215050 (cf. herein below under "In vivo investigation of CYPlAl/2 activity in rat after administration of ABR-215050 and ABR- 215050-dx"). In vivo studies in mouse also show that ABR-215050-dx retains a high therapeutic activity (cf. herein below under "In vivo investigation of anti-tumor effect of ABR-215050-dx in mouse").
Thus, according to the present invention, a deuterated ABR-215050 is provided which on administration gives rise to a substantially reduced CYP1 A induction while providing a high therapeutic activity. For the purpose of the present invention, the term "deuterium enrichment" at a specific position of a compound refers to the percentage of incorporation of deuterium at that position in place of hydrogen. For example, by "a compound having a 90 % deuterium enrichment at a given position" it is intended that 90 % of the molecules in a sample contain deuterium at the specified position. The natural abundance of deuterium is about 0.0156%, which means that the natural deuterium enrichment at any specific position of a compound is 0.0156 %. The deuterium enrichment can be determined using e.g. mass spectrometry and nuclear magnetic resonance spectroscopy. When referring to a moiety, such as a methyl group, comprising several positions capable of being deuterated, the term "deuterium enrichment" refers to a mean value, based on the individual values for the positions in the moiety. As an illustrating example, for a moiety having a deuterium enrichment of 90% and comprising three specific deuteration positions, the deuteration enrichment at each individual position e.g. may be 85%, 92% and 93%, (or any other percentage values) the mean of which is 90%.
For the purpose of the present invention, disorders ameliorated by the modulation of immune function e.g. comprise malignant hyperproliferative diseases, such as cancer, autoimmune diseases, inflammation and inflammatory diseases, and hypersensitivity disorders of the immune system.
By "modulation of immune function" is meant e.g. mitigation or prevention of an immune response that causes undesirable effects. As used herein, the terms "malignant hyperproliferative disease", "cancer" and "cancerous" refer to or describe a physiological condition in mammals that is typically characterized by unregulated cell growth. For the purpose of the present invention, examples of such a condition include, but are not limited to, melanoma, carcinoma, lymphoma, blastoma, sarcoma, and leukemia or lymphoid malignancies. More particular examples of such a condition include squamous cell cancer (e.g., epithelial squamous cell cancer), lung cancer including small-cell lung cancer, non-small cell lung cancer, adenocarcinoma of the lung and squamous carcinoma of the lung, cancer of the peritoneum, hepatocellular cancer, gastric or stomach cancer including gastrointestinal cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma, breast cancer, colon cancer, rectal cancer, colorectal cancer, endometrial cancer or uterine carcinoma, salivary gland carcinoma, kidney or renal cancer, prostate cancer, vulval cancer, thyroid cancer, hepatic carcinoma, anal carcinoma, penile carcinoma, as well as head and neck cancer.
The term "autoimmune disease" as used herein, refers to any disorder that occurs when the tissues of a living body are attacked by the body's own immune system. For the purpose of the present invention, examples of autoimmune diseases are: Acute Disseminated
Encephalomyelitis (ADEM), Acute necrotizing hemorrhagic leukoencephalitis, Addison's disease, Agammaglobulinemia, Allergic asthma, Allergic rhinitis, Alopecia areata,
Amyloidosis, Ankylosing spondylitis, Anti-GBM/Anti-TBM nephritis, Antiphospholipid syndrome (APS), Autoimmune aplastic anemia, Autoimmune dysautonomia, Autoimmune hepatitis, Autoimmune hyperlipidemia, Autoimmune immunodeficiency, Autoimmune inner ear disease (AIED), Autoimmune myocarditis, Autoimmune pancreatitis, Autoimmune retinopathy, Autoimmune thrombocytopenic purpura (ATP), Autoimmune thyroid disease, Axonal & neuronal neuropathies, Balo disease, Behcet's disease, Bullous pemphigoid, Cardiomyopathy, Castleman disease, Celiac sprue, Chagas disease, Chronic fatigue syndrome, Chronic inflammatory demyelinating polyneuropathy (CIDP), Chronic recurrent multifocal ostomyelitis (CRMO), Churg-Strauss syndrome, Cicatricial pemphigoid/benign mucosal pemphigoid, Crohn's disease, Cogans syndrome, Cold agglutinin disease, Congenital heart block, Coxsackie myocarditis, CREST disease, Essential mixed cryoglobulinemia, Demyelinating neuropathies, Dermatitis herpetiformis, Dermatomyositis, Devic's disease (neuromyelitis optica), Discoid lupus, Dressier' s syndrome, Endometriosis, Eosinophilic fasciitis, Erythema nodosum, Experimental allergic encephalomyelitis, Evans syndrome, Fibromyalgia, Fibrosing alveolitis, Giant cell arteritis (temporal arteritis), Glomerulonephritis, Goodpasture's syndrome, Graves' disease, Guillain-Barre syndrome, Hashimoto's
encephalitis, Hashimoto's thyroiditis, Hemolytic anemia, Henoch- Schonlein purpura, Herpes gestationis, Hypogammaglobulinemia, Idiopathic thrombocytopenic purpura (ITP), IgA nephropathy, IgG4-related sclerosing disease, Immunoregulatory lipoproteins, Inclusion body myositis, Insulin-dependent diabetes (typel), Interstitial cystitis, Juvenile arthritis, Juvenile diabetes, Kawasaki syndrome, Lambert-Eaton syndrome, Leukocytoclastic vasculitis, Lichen planus, Lichen sclerosus, Ligneous conjunctivitis, Linear IgA disease (LAD), Systemic Lupus Erythematosus (SLE), chronic Lyme disease, Meniere's disease, Microscopic polyangiitis, Mixed connective tissue disease (MCTD), Mooren's ulcer, Mucha-Habermann disease, Multiple sclerosis, Myasthenia gravis, Myositis, Narcolepsy, Neuromyelitis optica (Devic's), Neutropenia, Ocular cicatricial pemphigoid, Optic neuritis, Palindromic rheumatism, PANDAS (Pediatric Autoimmune Neuropsychiatry Disorders Associated with
Streptococcus), Paraneoplastic cerebellar degeneration, Paroxysmal nocturnal hemoglobinuria (PNH), Parry Romberg syndrome, Parsonnage-Turner syndrome, Pars planitis (peripheral uveitis), Pemphigus, Peripheral neuropathy, Perivenous encephalomyelitis, Pernicious anemia, POEMS syndrome, Polyarteritis nodosa, Type I, II, & III autoimmune polyglandular syndromes, Polymyalgia rheumatica, Polymyositis, Postmyocardial infarction syndrome, Postpericardiotomy syndrome, Progesterone dermatitis, Primary biliary cirrhosis, Primary sclerosing cholangitis, Psoriasis, Psoriatic arthritis, Idiopathic pulmonary fibrosis, Pyoderma gangrenosum, Pure red cell aplasia, Raynauds phenomenon, Reflex sympathetic dystrophy, Reiter's syndrome, Relapsing polychondritis, Restless legs syndrome, Retroperitoneal Fibrosis, Rheumatic fever, Rheumatoid arthritis, Sarcoidosis, Schmidt syndrome, Scleritis, Scleroderma, Sjogren's syndrome, Sperm & testicular autoimmunity, Stiff person syndrome, Subacute bacterial endocarditis (SBE), Susac's syndrome, Sympathetic ophthalmia,
Takayasu's arteritis, Temporal arteritis/Giant cell arteritis, Thrombocytopenic purpura (TTP), Tolosa-Hunt syndrome, Transverse myelitis, Ulcerative colitis, Undifferentiated connective tissue disease (UCTD), Uveitis, Vasculitis, Vesiculobullous dermatosis, Vitiligo, and Wegener's granulomatosis (11).
The term "hypersensitivity disorder" as used herein refers to a disorder such as allergy.
Examples of allergy are atopic dermatitis, allergic urticarial, hay fever, allergic asthma, anaphylaxis, food allergy (milk, egg, peanut, tree nut, seafood, soy, wheat), penicillin allergy, etc
The term "mammal" as used herein, includes a human as well as a non-human mammal, e.g. a horse, a pet animal, such as a cat or dog, a farm animal, such as a cow or sheep, or a laboratory animal such as a rat or monkey. Preferably the mammal is a human.
The term "treatment" as used herein includes prophylaxis as well as relieving the symptoms of disease. Thus, the term encompasses not only treating a patient to relieve the patient of the signs and symptoms of the disease or condition, or to ameliorate the condition of the patient suffering from the disease or disorder, but also prophylactically treating an asymptomatic patient to prevent the onset or progression of the disease or condition.
The term "effective amount" refers to an amount of a compound, which confers a therapeutic effect on the treated patient. The effect may be objective (i.e. measurable by some test or marker) or subjective (i.e. the subject gives an indication of or feels an effect).
As noted herein above, according to a first aspect, there is provided a compound which is deuterium enriched 4-hydroxy-5-methoxy-N,l-dimethyl-2-oxo-N-[(4- trifluoromethyl)phenyl] - 1 ,2-dihydro-quino line-3 -carboxamide, having a deuterium
enrichment in the amide-N methyl group of at least 70%, or a pharmaceutically acceptable salt thereof.
In some embodiments, the deuterium enrichment in the amide-N methyl group is at least 75%, or at least 80%, or at least 85%, e.g. at least 90%, or at least 95%, or at least 97%.
In some embodiments, the inventive compound is deuterated also at one or more other positions, i.e. it comprises a D instead of a H at a specific position which is not in the amide- N methyl moiety, at a deuterium enrichment in excess of 0.0156 %.
There also is provided a method of preparing a compound as defined herein above, by reacting a 4-hydroxy-5-methoxy-l-methyl-2-oxo-l,2-dihydro-quinoline-3-carboxylic acid C 1 -C4 alkyl ester with deuterated N-methyl-p-trifluoromethylaniline having a deuterium enrichment in the amide N-methyl group of at least 70%; in a suitable solvent; and optionally reacting the compound with a suitable pharmaceutically acceptable base.
In some embodiments, the deuterium enrichment in the N methyl group of N-methyl-p- trifluoromethylaniline is at least 75%, or at least 80%, or at least 85%, e.g. at least 90%, or at least 95%, or at least 97%.
In some embodiments, either 4-hydroxy-5-methoxy-l-methyl-2-oxo-l,2-dihydro-quinoline-3- carboxylic acid C 1 -C4 alkyl ester or N-methyl-p-trifluoromethylaniline, or both, is deuterated at one or more further positions. The "amide N" of 4-hydroxy-5-methoxy-N,l-dimethyl-2-oxo-N-[(4-trifluoromethyl)phenyl]- l,2-dihydro-quinoline-3-carboxamide also could be referred to as the "carboxamide N", i.e. it is the nitrogen of the 3-carboxamide moiety linking the phenyl ring moiety of the compound to the quinoline ring moiety. The "amide N-methyl", could also be referred to as the
"carboxamide N-methyl" and is the methyl group attached to the (carbox)amide nitrogen.
The pharmaceutically acceptable salt of the compound of the invention may be e.g. a base addition salt derived from sodium hydroxide, potassium hydroxide, calcium hydroxide, monoethanolamine, diethanolamine, dimethylaminoethanol or morpholine. und has the formula (I)
Figure imgf000013_0001
wherein
R is selected from H and pharmaceutically acceptable organic or inorganic cations; and R2, R3 and R4 are independently selected from H and D; and
CR2R3R4 has a total deuterium enrichment of at least 70%.
In some embodiments, R1 is H. In other embodiments, R1 is selected from pharmaceutically acceptable organic or inorganic cations, e.g. cations derived from sodium, potassium, calcium, monoethanolamine, diethanolamine, dimethylaminoethanol, and morpholine.
In formula (I), R2, R3 and R4 are independently selected from H and D, each one of R2, R3 and R4 having a deuterium enrichment such that CR2R3R4 has a total deuterium enrichment of about at least 70%. In some embodiments, the deuterium enrichment of CR2R3R4 is at least about 75%, or at least about 80%, or at least about 85%, e.g. at least about 90%, or at least about 95%, or at least about 97%.
For example, for a total deuterium enrichment of about at least 70%», the deuterium
enrichment of each one of R2, R3 and R4 should be at least about 89%; and for a deuterium enrichment of at least 97%, the deuterium enrichment of each one of R2, R3 and R4 should be at least about 99%.
Preferably, R2, R3 and R4 are all identical (R2 = R3 = R4), i.e. the compound of the invention a (Γ):
Figure imgf000014_0001
wherein R2 is selected from H and D and CR2 3 has a deuterium enrichment of at least 70%, or at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 97%. In view of this, it should be realized that, unless otherwise indicated or apparent from the context, any reference made herein to a compound of formula (I) also should be understood to apply to a compound of formula (Γ).
It should be realised that any of the other hydrogen atoms of the compound according to formula (I) also may be exchanged for a deuterium. That is, in addition to R2, R3 and R4, the compound of formula (I) may comprise up to 13 (when R1 is not H) or 14 (when Rl is H) further deuterium atoms replacing hydrogens in the compound of formula (I). Indeed, due to the natural distribution of deuterium a small fraction of the molecules in any given sample of the compound of formula (I) will comprise one or several deuterium atoms. However, the presence of such further deuterium atoms, either naturally or not, is not critical to the invention. Nonetheless, in some embodiments, the compound of formula (I) comprises at least one further deuterium atom at any specific location, other than in the amide-N methyl group, at a deuterium enrichment in excess of that which is naturally occurring, i.e. at an enrichment in excess of 0.0156 %, for example a deuterium enrichment of at least 1 %, or at least 5%, e.g. at least 10%. This further deuterium atom may replace a hydrogen atom at any location of the compound of formula (I). For example, one or more hydrogen atoms attached to any of the quinoline-N methyl group or the quinoline-O methyl group of the compound of formula (I) may be replaced by deuterium, and/or any of the aromatic hydrogens of the compound of formula (I) may be replaced by a deuterium. There also is provided a method for preparing a compound according to formula (I) as defined herein above; by reacting a compound of formula (II)
Figure imgf000015_0001
wherein R5 is a C1-C4 alkyl group;
of formula (III)
(I")
Figure imgf000015_0002
wherein R2, R3 and R4 are as defined herein above,
in a suitable solvent, and optionally reacting the compound of formula (I) wherein R1 is H, with a suitable, pharmaceutically acceptable base, e.g. NaOH, OH, Ca(OH)25
monoethanolamine, diethanolamine, dimethylaminoethanol, or morpholine. In the compound of formula (II), R5 may be a CI-C4 alkyl group, e.g. a CI -C3 alkyl group, such as methyl or ethyl, in particular methyl.
The compound of formula (II) may comprise a deuterium at one or more locations at a deuterium enrichment in excess of that which is naturally occurring. Likewise, in the compound of formula (III) any of the aromatic hydrogens may be replaced by a deuterium atom at a deuterium enrichment in excess of that which is naturally occurring.
The reaction between the compounds of formula (II) and (III) is performed in a suitable solvent medium. The reaction solvent medium may be e.g. a hydrocarbon such as a straight or branched chain C7-C10 alkane or a cycloalkane or a mixture of thereof, e.g. heptane, octane or decahydronaphthalene.
The compound of the invention is useful in therapy. Thus, in some embodiments, the invention provides a compound for use in the treatment of a malignant hyperproliferative condition, e.g. selected from melanoma, carcinoma, lymphoma, blastoma, sarcoma, and leukemia or lymphoid malignancies. In some particular embodiments, the invention provides a compound for use in the treatment of a malignant hyperproliferative condition selected from squamous cell cancer (e.g., . epithelial squamous cell cancer), lung cancer including small-cell lung cancer, non-small cell lung cancer, adenocarcinoma of the lung and squamous carcinoma of the lung, cancer of the peritoneum, hepatocellular cancer, gastric or stomach cancer including gastrointestinal cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma, breast cancer, colon cancer, rectal cancer, colorectal cancer, endometrial cancer or uterine carcinoma, salivary gland carcinoma, kidney or renal cancer, prostate cancer, vulval cancer, thyroid cancer, hepatic carcinoma, anal carcinoma, penile carcinoma, and head and neck cancer.
In some embodiments, the malignant hyperproliferative disease is selected from a solid tumor, malignant melanoma or a hematological tumor.
In some embodiments, the solid tumour is selected from adenocarcinoma, e.g. prostatic, breast, lung and colon-rectum cancers.
In some embodiments, the invention provides a compound for use in the treatment of an autoimmune disease, e.g an autoimmune disease as defined herein above.
In some particular embodiments, the autoimmune disease is selected from Crohn's disease, multiple sclerosis, rheumatoid arthritis, ulcerative colitis and systemic lupus erythematosus. Experimental
In vitro assay of CYP1A1 inducing capacity of ABR-215050
The mechanism for transcription of CYP1A1 involves the binding of the inducer to the Ah receptor followed by a translocation of the ligand-Ah-receptor complex to the nucleus, where it binds to specific enhancer sequences in the '-flanking region of the CYP1A1 gene. These sequences are referred to as xenobiotic responsive elements (XREs).
A luciferase gene reporter assay was used for the measurement of AhR mediated induction of CYP1A1. Human CYP1A1 promoters and 5 '-flanking sequences were cloned into firefly luciferase expression vectors and stably integrated into the human hepatoma cell line, HepG2 (8). The isolated cell line was renamed TV 1 OIL.
The cells were seeded in 96 well tissue culture plates 24-48 hours prior to treatment with the test compound. After the addition of ABR-215050 at a concentration of 1, 10 and 100 μΜ, the cells were further incubated for 12-24 hours. The cells were harvested by the addition of lysis buffer followed by a freezing/thawing cycle. An enzymatic assay was used for the determination of lucif erase activity. The results, expressed as the fold induction of lucif erase expression, are shown in Table 3 and in Fig. 1.
Figure imgf000017_0001
As a comparison, the same assay also was performed using benz(a)pyrene, a well-known, moderately strong CYP1A1 inducer. The results are shown in Fig. 2. The results of the in vitro assay show the extent of interaction of the tested compound with the Ah receptor, which mediates induction of both CYP1A1 and CYP1A2.
In vitro assay of CYP1A inducing capacity of ABR-215691
The same assay as used for ABR-215050 was used. The concentrations of ABR-215691 that were used and the results obtained, expressed as fold induction of luciferase expression, are shown in Table 4 and in Fig. 1.
Figure imgf000017_0002
In vivo investigation of pharmacokinetic characteristics of ABR-215050 and ABR-215050- dx in rat
A deuterated (also referred to as deuterium-enriched) ABR-215050 was synthesized, wherein the amide-N methyl moiety was trideuterated (ABR-215050-dx). This deuterated compound was diluted with non-deuterated ABR-215050 to a molar ratio of 1 : 1. The 1 : 1 equivalent molar mixture was administrated to rats in an in vivo experiment. Because of additional 13- carbon labeling in the quinoline scaffold, the formed amide-N demethyl metabolites could be measured selectively by means of HPLC-MS (High performance Liquid Chromatography with Mass Spectrometric detection). In Table 5, the plasma levels of ABR-215050-dx and ABR-215050 (in nM) measured in 4 different rats are shown, as well as the ratio of these two compounds.
Figure imgf000018_0001
From Table 5 it appears that the 1 :1 ratio of the deuterated vs. non-deuterated parent compounds remain essentially unchanged in the animals for up to at least 4 hours at a peroral dosage of 2.5 mg/kg.
The plasma levels of the ABR-215691 derived from ABR-215050-dx and ABR-215050 also were determined using LC-MS/MS and the results are shown in Table 6, which also shows the calculated ratio of the plasma levels of ABR-215691 derived from ABR-215050-dx and from ABR-215050, respectively as well as the calculated reduction of formation of amide-N demethyl metabolite.
Table 6 Plasma levels of ABR-215691 from ABR-215050-dx and ABR-215050 in rat after a peroral dose of 2.5 mg/kg at time 0 h.
Rat Time Plasma levels of Plasma levels Ratio of Reduction
No h ABR-215691from ABR-215691 from metabolite of amide-N
ABR-215050-dx ABR-215050 plasma levels demethylation nM nM % 1 1 64.0 265 0.24 75.8
2 2 93.9 318 0.30 70.5
3 3 46.6 192 0.24 75.7
4 4 94.6 372 0.25 74.6
Mean 74.8 286.8 0.26 74.1
From Table 6 it appears that the formation of ABR-215691 is substantially reduced by deuteration of the amide-N methyl group. The reduction of amide-N demethylation obtained by said deuteration ranges from 70.5 % to 75.8 % over 4 hours following peroral dosage. The results are illustrated in Fig. 5.
In vivo investigation of CYPlAl/2 activity in rat after administration of ABR-215050 and ABR-215050-dx
The in vivo induction of CYPlAl and CYP1A2 after repeated administration of ABR-215050 and of ABR-215050-dx, respectively, was studied in rat.
Test preparations
Test preparations B and C and blank preparation A were made as follows: For preparation B, ABR-215050 was dissolved in NaOH and sterile water at a concentration of 0.5 mg/mL. The pH of the solution was adjusted to pH 7.4-8.5. Preparation C was made in the same way, using ABR-215050-dx. Preparation A was a blank containing only water. The preparations were stored in a refrigerator for a maximum of one week before use. Table 7 summarizes preparation data.
Figure imgf000019_0001
Test animals
On arrival at the laboratory, the test animals were 9 weeks old Sprague Dawley male rats having a body weight of 250 g. They were divided into 3 groups and were allowed to acclimatize for at least 7 days before the test. During the whole acclimatization and test period, the animals received water and feed (Labfor R70, form Kimstad, Sweden) ad libitum, and were kept under a 12 hours dark/12 hours light cycle, at a temperature of 20 ± 2°C and a relative humidity of 50 ± 15 %.
Performance of test
Before administration of any test preparation, the body weight of each animal was measured and the individual dose to be administered to an animal was determined based on the weight of the animal. Administration was performed perorally during 4 days, cf. Table 8.
Figure imgf000020_0001
The animals were observed twice a day and weighed once a day. At any sign of reduced general condition, or at a weight loss of more than 15%, the rat was euthanized. Sampling
Shortly before the final dose administration, a blood sample was taken from vena saphena of rat No. 5. At the end of the administration period (on day 4), blood samples were taken in heparinized tubes in order to analyze the plasma levels of the administered compounds and amide-N demethylated metabolite. The samples were withdrawn from vena saphena (approx. 250 iL of blood) and from vena cava (maximum volume possible) according to the schedule indicated in Table 9.
Table 9 Sampling schedule
Rat No. Time (after final dose) of Time (after final dose) of sampling from vena saphena sampling from vena cava
1 - 24h 2 - 24h
3 - 24h
4 2h 24h
5 -4h* 24h
6 lh and 7h 24h
7 2h 24h
8 -4h* 24h
9 lh and 7h 24h
The sample is taken 4 hours before administration of final dose.
The samples were cooled in ice water and centrifuged at 1300xg, +4°C for 10 minutes as soon as possible after withdrawal (within 30 minutes). Plasma was collected, frozen and kept at -70°C until analysis.
Euthanization
At 24h after administration of the final dose, the animals were weighed and from each animal a final blood sample was withdrawn for a pharmacokinetic analysis. The animals then were euthanized and from each one the liver was withdrawn, weighed, and immediately frozen in crushed dry ice. The livers then were stored at -70°C until preparation of microsomes.
Preparation of microsomes
Microsomes were prepared according to the method M-0287 "Preparation of subcellular fractions from animal tissues" and then kept at -70°C until analysis.
Determination of protein concentration
The total protein concentration of the microsomal fraction was determined according to the method M-0289 "Determination of Protein according to Hartree".
Determination of CYPlAl/2 enzyme activity
The CYP1A1/2 enzyme activity was determined by incubation of the microsomal fraction with methoxyresorufin (MROD) and ethoxyresorufin (EROD), as CYP substrates, according to the method M-0272A, whereby EROD shows a higher specificity for CYP1A1, while MROD shows a higher specificity for CYP1A2. The results are shown in Table 10.
Figure imgf000022_0001
According to the data represented in Table 10 the observed mean fold induction of CYPlAl by ABR-215050 was 42, while ABR-215050-dx gave a mean fold induction of 11.5, which corresponds to a 73% reduction of the fold induction ((42-1 1.5)/42 xl00%) of CYPlAl . Table 1 1 also shows that ABR-215050 gave a mean fold induction of CYPl A2 of 17, while that obtained by administration of ABR-215050-dx was 5.5, i.e. a reduction of the fold induction of CYP1A2 of 68% ((17-5.5)/17 xl00%). The results are illustrated in Fig. 6.
In vivo investigation of anti-tumor effect of ABR-215050-dx in mouse
The anti-tumor effect of deuterated ABR-215050 was studied in mouse. Cell lines and culture conditions
The castration resistant subline LNCaP-19 was previously established from LNCaP cells (12). Cells were maintained as previously described (13). The LNCaP-19 cells were between passage 10 and 23 when used in the experiments. Passage 1 is defined as the first passage in our laboratory. The cells were tested and found free from mycoplasma.
Subcutaneous implantation of cells
Male athymic Nude BALB/c mice (age 8 weeks) were purchased from Taconic (Lille
Skensved, Denmark). For subcutaneous implantation, one million tumor cells suspended in 200μ1 Matrigel (BD Bioscience, Bedford, MA) were inoculated on the flank of the mice. The tumor size was measured by a caliper once a week throughout the experiment and the tumor take was 75% in the untreated control group (n=12). In the tumor growth experiment, ABR- 215050-dx (10 mg/kg day) was administered via drinking water from day 7. To assure appropriate dose was given with no significant fluctuations, water consumption was monitored for each animal cage during the entire experiment. It has previously been shown that the plasma half- life of tasquinimod is 3.4 hours, and that administration of 1-10 mg/kg/day via drinking water results in steady state plasma levels (0.4-1 μΜ) (14). Animals were sacrificed when the average tumor size for the control group reached a volume of 900 ± 100 mm3 or when the tumor volume for an individual animal reached 1200 mm3. The results are illustrated in Fig. 7.
The present invention is further illustrated in the following non-limiting Example.
EXAMPLE
4-Hydroxy-5-methoxy-N-deuteriomethyl-l-methyl-2-oxo-N-[(4-trifluoromethyl)phenyll-1.2- dihydroquinoline-3-carboxamide
4-Hydroxy-5-methoxy-l-methyl-2-oxo-l,2-dihydro-quinoline-3-carboxylic acid methyl ester (1.0 g, 3.79 mmol), N-deuteriomethyl-p-trifluoromethylaniline (1.0 g), tributylamine (100 microliter) and n-octane (70 mL) were heated to reflux and the volatiles were slowly distilled off during 6 hours. Approximately 60 mL solvents had distilled off at the end of the reaction and the mixture was cooled to room temperature. A mixture of n-heptane (25 mL) and toluene (6 mL) was added and the crystalline suspension was stirred for 20 min and the crystals were collected by filtration, washed with n-heptane, and dried to give the crude title compound
(1.52 g). This was dissolved in a mixture of methanol (11.2 mL), water (6.8 mL) and sodium hydroxide (5 M, 0.83 mL, 4.15 mmol). Hydrochloric acid (5 M) was added to adjust the pH to approximately 8-9 and the mixture was filtered to remove any insoluble material. To the filtrate was added 5 M HC1 until pH was approximately 2. The suspension was stirred for 1 hour and the crystals were collected by filtration, washed with 33 % aqueous MeOH and then with water, and finally were dried in vacuum to give the title compound (1.25 g, 80 %). H- nmr (CDC13); 9.95 (s, 1H), 7.50 (m, 5H), 6.93 (d, 1H), 6.70 (d, 1H), 4.04 (s, 3H), 3.55 (s, 3H). Anal. Calcd for C20H14N2D3O4F3: C 58.68, H 4.22, N 6.84. Found: C 58.8, H 4.25, N 6.94. Atmospheric pressure electrospray ionization (ESI) mass spectrometry: (M+H) calcd 410, found 410, cf. Fig. 3.
4-Hydroxy-5-methoxy-l-methyl-2-oxo-l,2-dihydro-quinoline-3-carboxylic acid methyl ester was prepared by a method as described in (15).
The N-deuteriomethyl-p-trifluoromethylaniline was prepared as follows. 4- aminobenzotrifluoride (12.6 mL, 100 mmol) was dissolved in THF (100 mL) and
trifluoroacetic anhydride (21.2 mL, 150 mmol) was added portionwise while cooling on an ice-bath. After complete addition the mixture was evaporated to give the trifluoroacetamide derivative as a white solid (26.1 g). This solid was dissolved in THF (100 mL) and cooled on an ice-bath. Potassium tert-butoxide (180 mmol, 20.2 g) and then deuterio methyl iodide (25 g, 173 mmol) were added portionwise followed by stirring at room temperature for 18 hours. The mixture was evaporated and partitionated between diethyl eter and water. The organic extract was washed with water and then brine and dried over sodium sulphate. Evaporation of the volatiles gave 2,2,2-trifluoro-N-deuteriomethyl-N-(4-trifluoromethyl-phenyl)-acetamide as a yellowish oil (27.3 g). This oil was dissolved in a mixture of methanol (125 mL) and ammonium hydroxide (28 % aqueous solution, 50 mL). After stirring at room temperature for 6 hours the mixture was concentrated and partitionated between diethyl eter and water. The organic extract was washed two times with water, then washed with brine and dried over sodium sulphate. Concentration gave a yellow oil that was purified on silica (heptane/ethyl acetate, 10: 1-5: 1) to give the title compound as a yellow oil (16.2 g, 91%). H-nmr (CDC13); 7.40 (d, 2H), 6.60 (d, 2H), 4.10 (s, 1H). Thus, by providing deuterium-enriched ABR-215050 having a deuterated amide-N methyl group, the present inventor has provided a method to (a) reduce a specified unwanted metabolite with well-defined unwanted property, (b) without affecting the half-life of the parent drug, and (c) without formation of metabolites with unknown properties compared to the not deuterated compound.
Since the deuterated ABR-215050 according to the invention has a substantially reduced CYP1A inducing effect, the present invention in particular enables combination therapy with drugs that are susceptible of metabolization by CYP1A.
In case the compound of the invention is used in combination with another drug, the two components may be in the same formulation or in separate formulations for administration simultaneously or sequentially. The compounds of the present invention may also be used or administered in combination with other treatment such as irradiation for the treatment of cancer.
It also is contemplated that the reduction of the Cytochrome P450 CYP1A induction will allow for a possibility of increasing the dosage of ABR-215050 (in the amide-N methyl deuterated form), if this should be desired, even in the presence of drugs that are metabolised by CYP1A.
According to one aspect of the invention, there is provided a method for the treatment of a mammal suffering from of a disorder ameliorated by the modulation of immune function, which comprises administering to the mammal an effective amount of a compound according to the invention, or a pharmaceutically acceptable salt thereof.
In some embodiments, the treatment includes prophylaxis as well as relieving the symptoms of disease or disorder.
In some embodiments, the treatment is for relieving the symptoms of the disease, i.e.
ameliorating the condition of the patient suffering from the disease or disorder. Further, there is provided a method for the treatment of a malignant hyperproliferative disorder, e.g a malignant hyperproliferative disorder as mentioned herein above, or an autoimmune disease, e.g an autoimmune disease as mentioned herein above, in a mammal by administering to the mammal an effective amount of a compound according to the invention, or a pharmaceutically acceptable salt thereof.
Effective quantities of the compounds of formula (I) are preferably administered to a patient in need of such treatment according to usual routes of administration and formulated in usual pharmaceutical compositions comprising an effective amount of the active ingredient and a suitable pharmaceutically acceptable carrier. Such compositions may take a variety of forms, e.g. solutions, suspensions, emulsions, tablets, capsules, and powders prepared for oral administration, aerosols for inhalations, sterile solutions for parental administration, and suppositories for rectal administration or suitable topical formulations. Conventional procedures for the selection and preparation of suitable pharmaceutical formulations are described, for example, in "Aulton's Pharmaceutics: The Design and Manufacture of Medicines", M.E. Aulton, Churchill Livingstone, 2007. A suitable daily dose for use in the treatment of cancer or an autoimmune disease is contemplated to vary between 0.0001 mg/kg to about 0.5 mg/kg body weight, in particular between 0.001 mg/kg to 0.05 mg/kg body weight, depending upon the specific condition to be treated, the age and weight of the specific patient, and the specific patient's response to the medication. The exact individual dosage, as well as the daily dosage, will be determined according to standard medical principles under the direction of a physician.
Various additives to enhance the stability or ease of administration of the drug are contemplated. The pharmaceutical composition may also contain additional therapeutically useful substances other than a compound of formula (I).
References
(1) PCT application WO 01/30758 Al.
(2) Isaacs J, Pili R, Qian D, Dalrymple S, Garrison J, Kyprianou N, Bjork A, Olsson A, Leandersson T. Identification of ABR-215050 as lead second generation quinoline-3- carboxamide anti-angiogenic agent for the treatment of prostate cancer. Prostate. 2006 Dec l;66(16):1768-78.
(3) Dalrymple S, Becker E, Isaacs J. The quinoline-3-carboxamide anti-angiogenic agent, tasquinimod, enhanced the anti-prostate cancer efficacy of androgen ablation and Taxotere without affecting serum PSA directly in human xenograft models. Prostate. 2007 67:790-797
(4) Clinical Phase-II study "EudraCT No: 2007-003470-26". (5) Trentham D. E. 1982. Collagen arthritis as a relevant model for rheumatoid arthritis. Evidence pro and con. Arthr. Rheum. 25, 911-916
(6) International patent application No. WO00/03991 (7) US patent application No. 2010/0055072 Al
(8) London, 13 December 2007 Doc. Ref. EMEA/CHMP/EWP/490784/2007
http://www.ema.europa.eu/docs/en GB/document librarv/Other/2009/1 l/WC500015483.pdf (9) Postlind, H., Vu, T.P., Tukey, R.H., and Quattrochi, L.C. (1993). Response of Human
CYP 1 -Luciferase Plasmids to 2,3,7,8-Tetrachlorodibenzo-p-dioxin and Polycyclic Aromatic Hydrocarbons. Toxicol. Appl. Pharmco. 118, 255-262
(10) Edward Kerns and Li Di. Drug-like Properties: Concepts, Structure Design and Methods: from ADME to Toxicity Optimization. Academic Press, 2008, ISBN 978-0-12-369520-8, p.139 (11) The American Autoimmune Related Diseases Association, Inc. (AARDA) 22100 Gratiot Ave. East Detroit, MI 48021, USA http://www. aarda.org/research_display .php?ID=47
(12) Gustavsson H, Welen , Damber JE. Transition of an androgen-dependent human prostate cancer cell line into an androgen- independent subline is associated with increased angiogenesis. Prostate. 2005;62:364-73.
(13) Jennbacken , Gustavsson H, Welen K, Vallbo C, Damber JE. Prostate cancer progression into androgen independency is associated with alterations in cell adhesion and invasivity. Prostate. 2006; 66:1631-40.
(14) Isaacs JT, Pili R, Qian DZ, Dalrymple SL, Garrison JB, yprianou N, Bjork A, Olsson A, Leanderson T. Identification of ABR-215050 as lead second generation quinoline-3- carboxamide anti-angiogenic agent for the treatment of prostate cancer. Prostate. 2006;
66:1768-78.
(15) Jonsson et al, J. Med. Chem., 2004, 47, 2075-2088.

Claims

Claims
1. A compound which is deuterium enriched 4-hydroxy-5-methoxy-N,l -dimethyl- 2-oxo-N- [(4-trifluoromethyl)phenyl]-l,2-dihydroquinoline-3-carboxamide, having a deuterium enrichment in the amide-N methyl group of at least 70%; or a salt thereof with a
pharmaceutically acceptable organic or inorganic cation.
2. A compound according to claim 1, wherein said deuterium enrichment is at least 90%..
3. A compound according to claim 1, having formula (I)
Figure imgf000029_0001
wherein
R1 is H or a pharmaceutically acceptable organic or inorganic cation; and
R2, R3 and R4 are independently selected from H and D; and
CR2R3R4 has a total deuterium enrichment of at least 70%.
4. A compound according to claim 3, wherein each one of R2, R3 and R4 has a deuterium enrichment of at least 90 %.
5. A compound according to any one of one the claims 1-4, wherein the pharmaceutically acceptable cation is derived from sodium, potassium, calcium, monoethanol amine, diethanolamine, dimethylaminoethanol, or morpholine.
6. A compound according to any one of the claims 1-5, for use as a medicament.
7. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to any one of the claims 1-5.
8. A compound according to any one of the claims 1-5, for use in the prevention or treatment of a disorder ameliorated by the modulation of immune function.
9. A compound according to any one of the claims 1-5, for use in the treatment of a disorder selected from a malignant hyperproliferative disorder and an autoimmune disease.
10. A compound according to claim 9, wherein the malignant hyperproliferative disorder is a solid tumor, malignant melanoma or a hematological tumor.
1 1. A compound according to claim 9, wherein the autoimmune disease is selected from Crohn's disease, multiple sclerosis, rheumatoid arthritis, ulcerative colitis and systemic lupus erythematosus.
12. A method of preparing a compound which is deuterium-enriched 4-hydroxy-5-methoxy- N,l-dimethyl-2-oxo-N-[(4-trifluoromethyl)phenyl]-l,2-dihydroquinoline-3-carboxamide, or a pharmaceutically acceptable salt thereof; by reacting a C1-C4 alkyl ester of 4-hydroxy-5- methoxy-l-methyl-2-oxo-l,2-dihydro-quinoline-3-carboxylic acid with deuterium-enriched N-methyl-p-trifluoromethylaniline wherein the N-methyl group has a deuterium enrichment of at least 70%, and optionally reacting the deuterium-enriched 4-hydroxy-5-methoxy-N,l- dimethyl-2-oxo-N-[(4-trifluoromethyl)phenyl]- 1 ,2-dihydro-quinoline-3-carboxamide with a pharmaceutically acceptable organic or inorganic base.
13. A method according to claim 12, wherein
a compound of formula (II)
Figure imgf000030_0001
wherein R5 is a C1-C4 alkyl group;
of formula (III)
Figure imgf000030_0002
wherein
R2, R3 and R4 are independently selected from H and D; and
CR2R3R4 has a total deuterium enrichment of at least 70%;
so as to obtain a compound of formula (I)
Figure imgf000031_0001
and optionally reacting the compound of formula (I) with a pharmaceutically acceptable organic or inorganic base.
14. A method according to claim 12 or claim 13, wherein the deuterium enrichment is at least 90%.
15. A method for the treatment of a malignant hyperproliferative disorder or an autoimmune disease in a mammal which comprises administering to the mammal an effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof.
PCT/EP2012/061798 2011-06-22 2012-06-20 Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide WO2012175541A1 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
US14/125,666 US9216956B2 (en) 2011-06-22 2012-06-20 Deuterium-enriched 4-hydroxy-5-methoxy-N,1-dimethyl-2-oxo-N-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide
CN201280030397.8A CN103796654B (en) 2011-06-22 2012-06-20 Deuterium enrichedization 4-hydroxy-5-methyl epoxide-N, 1-dimethyl-2-oxo-N-[(4-TRIFLUORO-METHYL) phenyl]-1,2-dihydroquinoline-3-Methanamide
KR1020147000764A KR20140035493A (en) 2011-06-22 2012-06-20 Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide
RU2014101775A RU2608306C2 (en) 2011-06-22 2012-06-20 Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide
BR112013031712-4A BR112013031712B1 (en) 2011-06-22 2012-06-20 COMPOUND 4-HYDROXY-5-METHOXY-N,1-DIMETHYL-2-OXO-N-[(4-TRIFLUOROMETHYL)-PHENYL]-1,2-DIHYDROQUINOLINE-3-CARBOXAMIDE ENRICHED IN DEUTERIUM, ITS USE, PHARMACEUTICAL COMPOSITION, AND, METHOD TO PREPARE A COMPOUND
AU2012274160A AU2012274160B2 (en) 2011-06-22 2012-06-20 Deuterium-enriched 4-hydroxy-5-methoxy-N,1-dimethyl-2-oxo- N-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide
EP12728565.8A EP2723340B1 (en) 2011-06-22 2012-06-20 Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide
CA2838947A CA2838947A1 (en) 2011-06-22 2012-06-20 Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide
JP2014516322A JP6034861B2 (en) 2011-06-22 2012-06-20 Deuterium-enriched 4-hydroxy-5-methoxy-N, 1-dimethyl-2-oxo-N-[(4-trifluoro-methyl) phenyl] -1,2-dihydroquinoline-3-carboxamide
ZA2013/09733A ZA201309733B (en) 2011-06-22 2013-12-23 Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161499848P 2011-06-22 2011-06-22
US61/499,848 2011-06-22
EP11171108.1 2011-06-22
EP11171108A EP2537517A1 (en) 2011-06-22 2011-06-22 Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide

Publications (1)

Publication Number Publication Date
WO2012175541A1 true WO2012175541A1 (en) 2012-12-27

Family

ID=44533811

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2012/061798 WO2012175541A1 (en) 2011-06-22 2012-06-20 Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide

Country Status (11)

Country Link
US (1) US9216956B2 (en)
EP (2) EP2537517A1 (en)
JP (1) JP6034861B2 (en)
KR (1) KR20140035493A (en)
CN (1) CN103796654B (en)
AU (1) AU2012274160B2 (en)
BR (1) BR112013031712B1 (en)
CA (1) CA2838947A1 (en)
RU (1) RU2608306C2 (en)
WO (1) WO2012175541A1 (en)
ZA (1) ZA201309733B (en)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013543504A (en) * 2010-10-14 2013-12-05 イムナール アクティエボラーグ 1,2-Dihydro-4-hydroxy-2-oxo-quinoline-3-carboxyanilide as an AHR activator
WO2014074381A1 (en) * 2012-11-07 2014-05-15 Teva Pharmaceutical Industries Ltd. Amine salts of laquinimod
US9233927B2 (en) 2013-03-14 2016-01-12 Teva Pharmaceutical Industries, Ltd. Crystals of laquinimod sodium and improved process for the manufacture thereof
KR20170083121A (en) * 2014-11-19 2017-07-17 액티브 바이오테크 에이비 Quinoline carboxamides for use in the treatment of leukemia
JP2017528473A (en) * 2014-09-23 2017-09-28 アクティブ バイオテック エイビー Quinoline carboxamide for use in the treatment of multiple myeloma
CN107427583A (en) * 2015-03-13 2017-12-01 益普生制药股份有限公司 The combination of his quinoline as medicine not moral or its pharmaceutically acceptable salt and PD 1 and/or PD L1 inhibitor
WO2021175924A1 (en) 2020-03-03 2021-09-10 Active Biotech Ab Tasquinimod or a pharmaceutically acceptable salt thereof for use in combination therapy
WO2022018240A1 (en) 2020-07-23 2022-01-27 Erasmus University Medical Center Rotterdam S100 proteins as novel therapeutic targets in myeloproliferative neoplasms
WO2022152902A1 (en) 2021-01-18 2022-07-21 Active Biotech Ab Tasquinimod or a pharmaceutically acceptable salt thereof for use in the treatment of myelodysplastic syndrome
WO2022248401A1 (en) 2021-05-25 2022-12-01 Active Biotech Ab A plurality of tasquinimod particles and use thereof
WO2023275248A1 (en) 2021-07-02 2023-01-05 Active Biotech Ab A pharmaceutical product containing tasquinimod and a method for assessing the purity of said product

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018105943A1 (en) * 2016-12-07 2018-06-14 순천향대학교 산학협력단 Pharmaceutical composition for treatment or alleviation of pulmonary fibrosis and asthma
IL293469B2 (en) * 2019-12-19 2024-04-01 Active Biotech Ab Compounds for treatment of eye diseases associated with excessive vascularisation

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000003991A1 (en) 1998-07-15 2000-01-27 Active Biotech Ab Quinoline derivatives
US6133285A (en) * 1998-07-15 2000-10-17 Active Biotech Ab Quinoline derivatives
WO2001030758A1 (en) 1999-10-25 2001-05-03 Active Biotech Ab Drugs for the treatment of malignant tumours
US20100055072A1 (en) 2008-09-03 2010-03-04 Auspex Pharmaceuticals, Inc. 2-oxo-1,2-dihydro-quinoline modulators of immune function

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2340735A1 (en) * 1976-02-11 1977-09-09 Roussel Uclaf NEW DERIVATIVES OF 3-QUINOLEINE CARBOXYLIC ACID, THEIR METHOD OF PREPARATION AND THEIR APPLICATION AS A MEDICINAL PRODUCT
RS51019B (en) * 1999-10-25 2010-10-31 Active Biotech Ab. Drugs for the treatment of malignant tumours
SE0201778D0 (en) * 2002-06-12 2002-06-12 Active Biotech Ab Process for the manufacture of quinoline derivatives

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000003991A1 (en) 1998-07-15 2000-01-27 Active Biotech Ab Quinoline derivatives
US6133285A (en) * 1998-07-15 2000-10-17 Active Biotech Ab Quinoline derivatives
WO2001030758A1 (en) 1999-10-25 2001-05-03 Active Biotech Ab Drugs for the treatment of malignant tumours
US20100055072A1 (en) 2008-09-03 2010-03-04 Auspex Pharmaceuticals, Inc. 2-oxo-1,2-dihydro-quinoline modulators of immune function

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
BRATT O ET AL: "Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer.", BRITISH JOURNAL OF CANCER 20 OCT 2009 LNKD- PUBMED:19755981, vol. 101, no. 8, 20 October 2009 (2009-10-20), pages 1233 - 1240, XP002662028, ISSN: 1532-1827 *
DALRYMPLE S; BECKER E; ISAACS J.: "The quinoline-3-carboxamide anti-angiogenic agent, tasquinimod, enhanced the anti-prostate cancer efficacy of androgen ablation and Taxotere without affecting serum PSA directly in human xenograft models", PROSTATE, vol. 67, 2007, pages 790 - 797
EDWARD KERNS; LI DI.: "Drug-like Properties: Concepts, Structure Design and Methods: from ADME to Toxicity Optimization", 2008, ACADEMIC PRESS, pages: 139
GUSTAVSSON H; WELEN K; DAMBER JE: "Transition of an androgen-dependent human prostate cancer cell line into an androgen-independent subline is associated with increased angiogenesis", PROSTATE, vol. 62, 2005, pages 364 - 73
ISAACS J; PILI R; QIAN D; DALRYMPLE S; GARRISON J; KYPRIANOU N; BJORK A; OLSSON A: "Leandersson T. Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer", PROSTATE, vol. 66, no. 16, 1 December 2006 (2006-12-01), pages 1768 - 78
ISAACS JT; PILI R; QIAN DZ; DALRYMPLE SL; GARRISON JB; KYPRIANOU N; BJORK A; OLSSON A; LEANDERSON T: "Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer", PROSTATE, vol. 66, 2006, pages 1768 - 78
JENNBACKEN K; GUSTAVSSON H; WELEN K; VALLBO C; DAMBER JE: "Prostate cancer progression into androgen independency is associated with alterations in cell adhesion and invasivity", PROSTATE, vol. 66, 2006, pages 1631 - 40
JONSSON ET AL., J. MED. CHEM., vol. 47, 2004, pages 2075 - 2088
M.E. AULTON: "Aulton's Pharmaceutics: The Design and Manufacture of Medicines", 2007, CHURCHILL LIVINGSTONE
POSTLIND, H.; VU, T.P.; TUKEY, R.H.; QUATTROCHI, L.C.: "Response of Human CYPl-Luciferase Plasmids to 2,3,7,8-Tetrachlorodibenzo-p-dioxin and Polycyclic Aromatic Hydrocarbons", TOXICOL. APPL. PHARMCO., vol. 118, 1993, pages 255 - 262
TRENTHAM D. E.: "Collagen arthritis as a relevant model for rheumatoid arthritis", EVIDENCE PRO AND CON. ARTHR. RHEUM., vol. 25, 1982, pages 911 - 916

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013543504A (en) * 2010-10-14 2013-12-05 イムナール アクティエボラーグ 1,2-Dihydro-4-hydroxy-2-oxo-quinoline-3-carboxyanilide as an AHR activator
WO2014074381A1 (en) * 2012-11-07 2014-05-15 Teva Pharmaceutical Industries Ltd. Amine salts of laquinimod
US8975279B2 (en) 2012-11-07 2015-03-10 Teva Pharmaceutical Industries, Ltd. Amine salts of laquinimod
US9233927B2 (en) 2013-03-14 2016-01-12 Teva Pharmaceutical Industries, Ltd. Crystals of laquinimod sodium and improved process for the manufacture thereof
US9956212B2 (en) 2014-09-23 2018-05-01 Active Biotech Ab Quinoline carboxamides for use in the treatment of multiple myeloma
US10314836B2 (en) 2014-09-23 2019-06-11 Active Biotech Ab Quinoline carboxamides for use in the treatment of multiple myeloma
JP2017528473A (en) * 2014-09-23 2017-09-28 アクティブ バイオテック エイビー Quinoline carboxamide for use in the treatment of multiple myeloma
US10300053B2 (en) 2014-11-19 2019-05-28 Active Biotech Ab Quinoline carboxamides for use in the treatment of leukemia
KR20170083121A (en) * 2014-11-19 2017-07-17 액티브 바이오테크 에이비 Quinoline carboxamides for use in the treatment of leukemia
KR102525805B1 (en) 2014-11-19 2023-04-25 액티브 바이오테크 에이비 Quinoline carboxamides for use in the treatment of leukemia
CN107427583A (en) * 2015-03-13 2017-12-01 益普生制药股份有限公司 The combination of his quinoline as medicine not moral or its pharmaceutically acceptable salt and PD 1 and/or PD L1 inhibitor
CN107427583B (en) * 2015-03-13 2020-12-29 活跃生物技术有限公司 Combination of Taquinomod or a pharmaceutically acceptable salt thereof with a PD-1 and/or PD-L1 inhibitor for use as a medicament
RU2742373C2 (en) * 2015-03-13 2021-02-05 Эктив Байотек Аб Combination of tasquinimod or its pharmaceutically acceptable salt and pd-1 and/or pd-l1 inhibitor for use as a medicinal agent
WO2021175924A1 (en) 2020-03-03 2021-09-10 Active Biotech Ab Tasquinimod or a pharmaceutically acceptable salt thereof for use in combination therapy
WO2022018240A1 (en) 2020-07-23 2022-01-27 Erasmus University Medical Center Rotterdam S100 proteins as novel therapeutic targets in myeloproliferative neoplasms
WO2022152902A1 (en) 2021-01-18 2022-07-21 Active Biotech Ab Tasquinimod or a pharmaceutically acceptable salt thereof for use in the treatment of myelodysplastic syndrome
WO2022248401A1 (en) 2021-05-25 2022-12-01 Active Biotech Ab A plurality of tasquinimod particles and use thereof
WO2023275248A1 (en) 2021-07-02 2023-01-05 Active Biotech Ab A pharmaceutical product containing tasquinimod and a method for assessing the purity of said product

Also Published As

Publication number Publication date
AU2012274160A1 (en) 2014-01-23
AU2012274160B2 (en) 2016-12-15
EP2723340B1 (en) 2017-11-22
US20140112946A1 (en) 2014-04-24
RU2014101775A (en) 2015-07-27
CN103796654A (en) 2014-05-14
KR20140035493A (en) 2014-03-21
US9216956B2 (en) 2015-12-22
BR112013031712B1 (en) 2022-03-08
CN103796654B (en) 2016-08-17
JP6034861B2 (en) 2016-11-30
EP2537517A1 (en) 2012-12-26
ZA201309733B (en) 2015-08-26
BR112013031712A2 (en) 2017-07-04
AU2012274160A2 (en) 2014-07-17
JP2014517051A (en) 2014-07-17
CA2838947A1 (en) 2012-12-27
EP2723340A1 (en) 2014-04-30
RU2608306C2 (en) 2017-01-17

Similar Documents

Publication Publication Date Title
AU2012274160B2 (en) Deuterium-enriched 4-hydroxy-5-methoxy-N,1-dimethyl-2-oxo- N-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide
WO2021190467A1 (en) Spiro ring-containing quinazoline compound
JP6654646B2 (en) Quinoline derivatives as TAM RTK inhibitors
CN105153122B (en) [(indol-3-yl) pyrimidine -2-base] aminophenyl propyl- 2- alkenylamide derivatives and salt, preparation method, application
ES2798424T3 (en) Triazolopyridine Compounds and Uses of These
CN112543758A (en) Pharmaceutically acceptable salts of sepiapterin
BR112020003865A2 (en) pharmaceutical compositions comprising sepiapterin and their uses
CN115433187B (en) Crystalline form composition of salt of fused tetracyclic or pentacyclic dihydro-diazepin carbazolone and use thereof
BR112014009084B1 (en) ARRY-380 CRYSTALLINE POLYMORPHS
ES2959891T3 (en) Production of trans-[tetrachlorobis(1H-indazole)ruthenate (III)] and compositions thereof
WO2022063297A1 (en) Quinazoline derivative, preparation method therefor and use thereof
WO2020156189A1 (en) Camptothecin derivative and water-soluble prodrug thereof, pharmaceutical composition containing same, preparation method, and use
ES2928666T3 (en) Pyridinethiones, their pharmaceutical compositions and their therapeutic use for the treatment of proliferative, inflammatory, neurodegenerative or immune-mediated diseases
WO2022002100A1 (en) Novel benzimidazole compound
ES2844425T3 (en) Crystalline polymorphic form of 3-hydroxy-4,5-bis-benzyloxy-6-benzyloxymethyl-2-phenyl-2-oxo-2lambda5- [1,2] oxaphosphinan
WO2023143210A1 (en) Phthalazinone compounds, preparation method therefor, pharmaceutical composition containing phthalazinone compounds and uses thereof
WO2023143147A1 (en) Pyridazopyridone compounds, pharmaceutical composition thereof and use thereof
EP3315493B1 (en) Phenyl amino pyrimidine compound or polymorph of salt thereof
CN115504976A (en) Adagrasib crystal form and preparation method thereof
TWI831325B (en) Naphthyridine derivatives as ATR inhibitors and preparation methods thereof
US11111234B2 (en) Salt of a quinazoline derivative-like tyrosine kinase inhibitor and crystal form thereof
US10100005B1 (en) Mesalazine derivatives
WO2023116763A1 (en) Pyridazine compound, and pharmaceutical composition and use thereof
CN115244054A (en) Crystals of hypoxanthine compound
BR122024013534A2 (en) PHARMACEUTICALLY ACCEPTABLE SALTS AND COCRYSTALS OF SEPIAPTERIN, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, AND THEIR USES

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12728565

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2838947

Country of ref document: CA

Ref document number: 2014516322

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 14125666

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20147000764

Country of ref document: KR

Kind code of ref document: A

REEP Request for entry into the european phase

Ref document number: 2012728565

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2014101775

Country of ref document: RU

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2012274160

Country of ref document: AU

Date of ref document: 20120620

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112013031712

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112013031712

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20131209